治疗罕见癌症的外体细胞:进展和临床翻译
Kavitha Unnikrishnan1,2, Abhay Mahesh3, Ram Mohan Ram Kumar3
1Cancer Research Program, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Thiruvananthapuram, India.
ChemMedChem
|February 19, 2026
概括
基于外体的疗法在罕见癌症中表现有前途,提供向的药物输送和改善的结果. 需要进一步的研究来探索它们在这些具有挑战性的恶性瘤中的临床应用.
科学领域:
- 在瘤学瘤学.
- 纳米技术纳米技术
- 生物技术是生物技术.
背景情况:
- 由于诊断延迟和有限的向治疗,罕见癌症存在重大治疗挑战.
- 作为天然纳米载体的外体被设计用于药物输送,免疫调节和克服耐药性.
- 它们在罕见癌症中的潜力正在出现,解决尚未满足的临床需求.
研究的目的:
- 审查目前关于用于罕见癌症的基于外体的治疗方法的证据.
- 突出外体的治疗潜力,克服罕见恶性瘤独特的挑战.
- 探索用于个性化和有效的罕见癌症治疗的外体驱动策略.
主要方法:
- 对罕见癌症外体基干预的临床前和早期临床研究的文献综述.
- 分析与向药物输送和瘤微环境调制相关的外体性质.
- 在癌症进展中对外体衍生细胞通信的评估.
主要成果:
- 外体体显示出有针对性地提供治疗药物的潜力,增强有效载荷稳定性和减少罕见癌症模型中的毒性.
- 工程外体可以调节瘤微环境,免疫反应,克服药物耐药性.
- 初步证据表明,外体细胞可以影响关键的癌症进展过程,如血管新生和免疫逃避.
结论:
- 基于外体的疗法代表了罕见癌症治疗的前沿前沿,提供个性化和有效的解决方案.
- 尽管临床应用尚未得到充分研究,但外基因组具有显著的潜力,可以改善罕见癌症患者的治疗结果.
- 对外体驱动策略的进一步研究对于推进罕见癌症疗法至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
9.2K
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
8.7K
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Cystic Fibrosis: Management
657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
657
